Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC)

NCT02283021 | Unknown DMC

• 1 other identifier: CALCIUM-HMO-CTIL
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

Calcium is an extremely important ion used in our body for many processes. One of its tasks is to control gene expression. Cells intake calcium from their surroundings though special calcium channels located on the surface membranes of the cells. The great many studies on such calcium channels were performed on excitable cells such as muscle, heart or neuronal cells, where the calcium ions are controlled by voltage. Surprisingly, not much is known about the identity of calcium subunits in non-excitable cells like epithelial cells (which compose most of the connective tissue in the body), liver cells, lung cells, immune system cells, etc. Recently, the investigators have shown that calcium channels from muscles are, in fact, expressed in T cells of the immune system, where they are used for proliferation. The investigators postulated that probably other cell types, especially cancerous cell types, might be using these subunits similarly. The aim of this study is to determine the identity and sequence of calcium subunits expressed in non-small cell Lung Carcinoma (NSCLC), which accounts for 80% of the worldwide lung cancer deaths.

Conditions

NSCLC

Keywords

expression of L-type calcium subunits

Outcome Measures

Primary Outcomes (1)

• mRNA expression and sequence of calcium channel subunits in NSCLC

  mRNA will be extracted from each sample biopsy followed by real time PCR analysis. If any calcium subunit is detected, semi quantitative PCR will be performed, PCR bands will be cloned and sequenced.

  up to 1 month per patient

Study Arms (2)

NSCLC Patients

Sample biopsies from normal and cancerous lung tissue.

Other: A biopsy sample

Patients without NSCLC

Sample biopsies from normal lung tissue.Control group.

Other: A biopsy sample

Interventions

A biopsy sample OTHER

Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.

NSCLC Patients; Patients without NSCLC

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients diagnosed with NSCLC and patients not diagnosed with NSCLC

You may qualify if:

• NSCLC patients
• Patients without NSCLC
• Men or woman between 18-80 years of age

You may not qualify if:

• Pregnant woman

Sponsors & Collaborators

• Hadassah Medical Organization: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Lung specimen biospsies are routinely taken from NSCLC patients and sent to pathological evaluation. We will obtain small samples from these biopsies from the pathologist, which are normally discarded. mRNA will be extracted from these samples.

Study Officials

• Hadas Lamberg, PhD

  Hadassah Medical Organization

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 5, 2014
• First Posted: November 5, 2014
• Study Start: January 1, 2015
• Primary Completion: January 1, 2017
• Study Completion: January 1, 2018
• Last Updated: August 20, 2015

Record last verified: 2015-08